IP Library Granted Patent US 7,923,547
Granted Patent B2
US 7,923,547 · App. 11/499,529 · Granted Apr 12, 2011

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,923,547
App. No.
11/499,529
Granted
Apr 12, 2011
Kind
B2
Abstract

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.

Claims (8)

1. A chemically modified double-stranded short interfering nucleic acid molecule that mediates RNA interference (RNAi) and comprising a sense strand and an antisense strand that are not connected via a linker molecule, wherein:

a) each strand of said nucleic acid molecule is independently 18 to 24 nucleotides in length;

b) a nucleotide sequence of the antisense strand of said nucleic acid molecule is complementary to a mammalian target RNA sequence;

c) the short interfering nucleic acid molecule has between 17 and 23 base pairs;

d) the sense strand comprises 10 or more 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, or universal base modified nucleotides, and a plurality of pyrimidine nucleotides present in the sense strand are 2′-deoxy-2′-fluoro pyrimidine nucleotides and a plurality of purine nucleotides present in the sense strand are 2′-deoxy purine nucleotides; and

e) the antisense strand comprises 10 or more 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, or universal base modified nucleotides, and a plurality of pyrimidine nucleotides present in the antisense strand are 2′-deoxy-2′-fluoro pyrimidine nucleotides and a plurality of purine nucleotides present in the antisense strand are 2′-O-methyl purine nucleotides.

2. The nucleic acid molecule of claim 1 , wherein the sense strand comprises an inverted deoxy abasic modification at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends.

3. The nucleic acid molecule of claim 1 , wherein the antisense strand comprises one or more phosphorothioate internucleotide linkages.

Assignments (2)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2008
From: MCSWIGGEN, JAMES; CHOWRIRA, BHARAT; MACEJAK, DENNIS; ZINNEN, SHAWN; PAVCO, PAMELA; HAEBERLI, PETER; MORRISSEY, DAVID; FOSNAUGH, KATHY; JAMISON, SHARON; USMAN, NASSIM; THOMPSON, JAMES; VARGEESE, CHANDRA; WANG, WEIMIN; CHEN, TONGQIAN; VAISH, NARENDRA; BEIGELMAN, LEONID
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 021123/0488 →